RxDoctor Payments Data

Virginia Delon

Adult Health · Marion, INNPI 1083804124

Payments from drug & device makers

$990in general payments, 2019–2025

Across 57 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$592
  • Novo Nordisk$135
  • AstraZeneca$131
  • Lilly USA, LLC$101
  • Otsuka America Pharmaceutical, Inc.$16
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$16

What the payments were for

  • Food & beverage$990100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$990 in reported general payments places this provider in the 65th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$9,207
Medicare patients
24
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl21$30,336
OzempicSemaglutide17$24,920
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,865
VyvanseLisdexamfetamine Dimesylate15$5,731
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine85$2,544
Albuterol Sulfate HfaAlbuterol Sulfate70$2,028
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$1,099
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen36$1,093
Gabapentin57$1,026
Hydroxyzine Hcl34$982
Ventolin HfaAlbuterol Sulfate11$864
Tramadol Hcl56$703
Alprazolam26$559
ValacyclovirValacyclovir Hcl11$503
Acetaminophen-CodeineAcetaminophen With Codeine15$438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$592$30,33621 claims
Novo NordiskOzempic$135$24,92017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 391 adult health providers in Indiana.

Other adult health in Marion

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →